Trial reportBritish journal of anaesthesia2026
Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study.
Trial report in British journal of anaesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04607122 (Interest of Low-dose Landiolol Administration After Cardiac Surgery for the Prevention of Postoperative Atrial Fibrillation), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interest of Low-dose Landiolol Administration After Cardiac Surgery for the Prevention of Postoperative Atrial Fibrillation
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dexmedetomidine for the prevention of postoperative atrial fibrillation: A systematic review and meta-analysis.The Journal of international medical research · 2026Pooled it
- Beta-blockers for prevention of atrial fibrillation in cardiac surgery.Journal of thoracic disease · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative atrial fibrillation (POAF) affects 30% of patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Beta-blockers are the first-line agents recommended for POAF prevention. Landiolol, an ultra-short-acting, highly selective beta-1-blocker, has been shown to be effective in reducing POAF in Asian patients at a low dose of 2 μg kg
methodsThis multicentre, double-blind, randomised, placebo-controlled superiority trial was conducted from January 2021 to July 2023 at three hospitals in France. Participants were non-Asians ≥65 yr undergoing elective cardiac surgery with CPB and a left ventricular ejection fraction ≥40%. Treatment was started in the ICU and continued for up to 24 h, after which oral beta-blockers were administered. The primary endpoint was the incidence of POAF while in the ICU, analysed by intention to treat. Secondary outcomes included in-hospital and 30-day POAF, ICU and hospital length of stay, and safety outcomes.
resultsA total of 318 participants (mean age: 71 [range: 68-76] yr; 21.4% female) were randomised. POAF in ICU occurred in 51/160 (31.9%) participants who received placebo, compared with 47/158 (29.8%) who received a low-dose landiolol infusion (relative risk: 0.93 [95% confidence interval, 0.67-1.30]; P=0.77). No differences were observed in secondary endpoints, including in-hospital POAF and safety outcomes.
conclusionsIn non-Asian patients undergoing cardiac surgery with CPB, a low-dose 24-h infusion of landiolol, used as a bridge to oral beta-blockers, did not reduce the incidence of postoperative atrial fibrillation. CLINICAL
trial registrationClinicalTrials.gov (NCT04607122).
Indexed as
Identifiers
41203473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.